---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-274093"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-06-17T20:00:15+00:00"
generated_at: "2026-06-17T20:01:20.502511+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Damora Therapeutics shareholders elect directors, approve say-on-pay and E&Y ratification at 2026 annual meeting

## Summary
- Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.
- Advisory say-on-pay approved: 51,401,988 for, 3,546 against, 27,018 abstain.
- Say-on-frequency: one-year option received 50,913,167 votes; Board adopts annual frequency.
- Ratified Ernst & Young as auditor for FY2026: 54,977,317 for, 5,640 against, 26,981 abstain.
- Quorum of 55,009,938 shares out of 60,303,212 outstanding was represented.

## SEC filing metadata
- accession: 0001193125-26-274093
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-06-17T20:00:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/dmra-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-274093
- JSON: https://secwatch.observer/filing/0001193125-26-274093.json
- Plain text: https://secwatch.observer/filing/0001193125-26-274093.txt

## Key facts
- Shareholder Votes
  Damora Therapeutics, Inc. shareholders approved Election of Michael Landsittel and Cameron Turtle, D.Phil as Class III directors at the 2026-06-17 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: 1. Election of Directors Proposal . Nominees For Withheld Broker Non-Votes Michael Landsittel 51,403,541 29,011 3,577,386 Cameron Turtle, D.Phil 51,403,540 29,012 3,577,386
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm
- Shareholder Votes
  Damora Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation paid to the named executive officers at the 2026-06-17 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: 2. Say-on-Pay Proposal . For Against Abstain Broker Non-Votes 51,401,988 3,546 27,018 3,577,386
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm
- Shareholder Votes
  Damora Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve executive compensation at the 2026-06-17 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: 3. Say-on-Frequency Proposal . 1 Year 2 Years 3 Years Abstain 50,913,167 103 518,015 1,267
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm
- Shareholder Votes
  Damora Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: 4. Ratification of Auditor Proposal . For Against Abstain Broker Non-Votes 54,977,317 5,640 26,981 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.